The first data on CD26-expressing primary lung cancer cells treated with the CD26 inhibitor vildagliptin that we present in this study showed that upon increasing the doses of vildagliptin, tumor cell colonies were reduced, indicating also here a tumor-inhibitory effect by a gliptin. This evidence concerns the gene DPP4 and lung carcinoma.